Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck, Pfizer Finalize Deal To Co-promote Xalkori | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck, Pfizer Finalize Deal To Co-promote Xalkori

Will roll-out in two waves

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and Merck have finalized their co-promotion agreement regarding the former’s anaplastic lymphoma kinase (ALK) inhibitor, XALKORI (crizotinib) for the treatment of non-small cell lung cancer. The co-promotion will occur in two waves. The first, beginning in Q2 and Q3, will roll out in the U.S., Canada, Japan and five European countries—France, Germany, Italy, Spain and the UK. In the U.S. and Canada, XALKORI will be co-promoted by EMD Serono, Merck KGaA’s arm in these countries. The second wave, in China and Turkey, will start in 2016.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters